Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia.
Severe fetomaternal alloimmune thrombocytopenia requires urgent treatment with compatible platelet concentrates. As prompt treatment is sometimes delayed owing to the unavailability of compatible platelets, we established an accredited platelet donor panel to provide effective and timely transfusion support for fetal and neonatal therapy. After a mass screening programme of over 60,000 blood donations, 45 HPA-1a-negative donors with no antibodies to HPA, HLA, red cell antigens and granulocytes/lymphocytes, and with low titre anti-A and/or -B were accredited. All accredited donors were fully genotyped for HPA-1, -2, -3 and -5 by PCR-SSP. Ninety-one per cent of the accredited donors were also negative for HPA-5b.
Ranasinghe
E
E
National Blood Service East Anglia Centre, Cambridge, UK. edmund.ranasinghe@nbs.nhs.uk
Walton
J D
JD
Hurd
C M
CM
Saul
L
L
Smith
G
G
Campbell
K
K
Ouwehand
W H
WH
D016824:Antigens, Human Platelet; D001782:Blood Donors; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D039661:Integrin beta3; D017713:Platelet Transfusion; D010983:Plateletpheresis; D011247:Pregnancy; D013921:Thrombocytopenia / Q000196:embryology / Q000628:therapy*
C055973:5b alloantigen, human; D016824:Antigens, Human Platelet; C061248:ITGB3 protein, human; D039661:Integrin beta3